found that the frequency of CD14+ CD16− HLA‐DRhi monocytes in peripheral blood is a strong predictor of survival in response to anti‐PD‐1 therapy in melanoma patients.[135] Similarly, Zhang et al. This evidence concerns the gene PDCD1 and melanoma.